 Patients with tissue-proven neuroblastic tumors receiving 18F-FDOPA PET or 123I-MIBG at initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of 18F-FDOPA or 123I-MIBG PET were compared to each other and compared to18F-FDG PET, using tumor histology as the standard. 